Role of Dopamine Receptors in Primary Focal Dystonias

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01373840

Enrollment

Registered

2011-06-15

Start date

2011-09-30

Completion date

2016-04-30

Last updated

2018-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Focal Dystonias, Healthy

Keywords

focal, dystonia, dopamine, receptor

Brief summary

Dystonia is a disabling movement disorder characterized by repetitive patterned or sustained muscle contractions causing twisting or abnormal postures that may afflict 250,000 people in the U.S. While the pathophysiology of dystonia remains uncertain the treatment is rather rudimentary. A better understanding of neural mechanisms of dystonias is not only an invaluable prerequisite for developing better treatment options but also a step toward better understanding of the complex network of basal ganglia. In this study I will investigate if there is any difference between the dopamine receptors and dopamine in people with dystonia and healthy subjects.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Age \>20 * Male or Female * Any race or ethnicity * Primary focal dystonia (arm or cranial) * Ability to give informed consent

Exclusion criteria

* Family history of dystonia * Pregnancy (confirmed with negative urine pregnancy test in women of child bearing potential), breastfeeding * Exposure to radiation therapy * Any MRI contraindications such as foreign metallic implants, pacemaker, and aneurysm clip etc. * History of cardiac disease, uncontrolled hypertension, abnormal EKG during screening phase * History of exposure to any drugs affecting dopaminergic systems within the last 6 months (e.g. dopamine receptor blocking agents, cocaine, amphetamine, tetrabenazine, reserpine, L-dopa, dopamine agonists, as they might affect the dopamine receptor binding or endogenous dopamine). * Active depression (Beck Depression Inventory\_II \>14) * Cognitive impairment (Mini-Mental State Score \<27) * CNS active medications such as gabapentin or narcotics, muscle relaxants which might be given for pain in the 3 days prior to study * History of stroke, seizure, cerebral palsy, generalized dystonia, parkinsonism, inability to hold head still during the scanning time.

Countries

United States

Outcome results